Fullerton purchased 100,000 shares resulting in an average purchase price of $3.01 per share.
It also increased his overall holding in the company to 1.07 million shares.
Fullerton purchase follows recent CEO purchase
Fullerton’s purchase follows CEO Paul Rennie’s recent purchase of 197,355 shares for $578,250.
This increased Rennie’s overall holding to 23.61 million shares, making him a substantial holder in the company.
One of the ASX’s leading biotech companies
Paradigm is a late-stage ASX-listed biotechnology company focused on repurposing Pentosan Polysulfate Sodium (PPS), an FDA-approved drug that has a long track record of safely treating inflammation over 60 years
Its main focus is on repurposing PPS (under the name ZILOSUL®) to treat osteoarthritis (OA) – market with over 31 million sufferers in the US alone.
Paradigm expects to file an investigational new drug (IND) application with the FDA for a phase 3 clinical trial in OA in early 2020, potential for trial readout and regulatory submission in the US as early as 2021.